File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West.

TitleContrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West.
Authors
KeywordsBridging therapy
hepatocellular carcinoma
targeted therapy
transarterial chemoembolisation
transarterial radioembolisation
Issue Date2019
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
Citation
Clinical Oncology, 2019, v. 31 n. 8, p. 560-569 How to Cite?
AbstractHepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC. © 2019 The Royal College of Radiologists
Persistent Identifierhttp://hdl.handle.net/10722/276319
ISSN
2023 Impact Factor: 3.2
2023 SCImago Journal Rankings: 0.907
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, VHF-
dc.contributor.authorSeong, J-
dc.contributor.authorYoon, SM-
dc.contributor.authorWong, CLT-
dc.contributor.authorWang, B-
dc.contributor.authorZhang, JL-
dc.contributor.authorChiang, CL-
dc.contributor.authorHo, PYP-
dc.contributor.authorDawson, LA-
dc.date.accessioned2019-09-10T03:00:37Z-
dc.date.available2019-09-10T03:00:37Z-
dc.date.issued2019-
dc.identifier.citationClinical Oncology, 2019, v. 31 n. 8, p. 560-569-
dc.identifier.issn0936-6555-
dc.identifier.urihttp://hdl.handle.net/10722/276319-
dc.description.abstractHepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC. © 2019 The Royal College of Radiologists-
dc.languageeng-
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon-
dc.relation.ispartofClinical Oncology-
dc.subjectBridging therapy-
dc.subjecthepatocellular carcinoma-
dc.subjecttargeted therapy-
dc.subjecttransarterial chemoembolisation-
dc.subjecttransarterial radioembolisation-
dc.titleContrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West.-
dc.typeArticle-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailWong, CLT: wongtcl@hku.hk-
dc.identifier.emailChiang, CL: chiangcl@hku.hk-
dc.identifier.emailHo, PYP: pattyho@hku.hk-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityWong, CLT=rp01679-
dc.identifier.authorityChiang, CL=rp02241-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clon.2019.06.002.-
dc.identifier.pmid31279433-
dc.identifier.scopuseid_2-s2.0-85067346432-
dc.identifier.hkuros303258-
dc.identifier.hkuros304502-
dc.identifier.hkuros304680-
dc.identifier.hkuros312954-
dc.identifier.volume31-
dc.identifier.issue8-
dc.identifier.spage560-
dc.identifier.epage569-
dc.identifier.isiWOS:000473609300010-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0936-6555-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats